Grow Taller 4 Idiots

How to Grow Taller

Get Instant Access

1. Molitch ME. Prolactin. In: Melmed M, ed. The Pituitary. Cambridge, MA: Blackwell Science; 1995:164-166.

2. Molitch ME. Prolactinoma. In: Melmed M, ed. The Pituitary. Cambridge, MA: Blackwell Science; 1995:443-477.

3. Webster J. Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13(3):395-408.

4. Biller BMK, Baum HBA, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692.

5. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75:698.

6. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807.

7. Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000;52:319.

8. Fahie-Wilson MN, Soule SG. Macroprolactinemia: contribution to hyperprolactinemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252-258.

9. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol 1996;44:305-309.

10. Sawers HA, Robb OJ, Walmsley D, Strachan FM, Shaw J, Bevan JS. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia. Clin Endocrinol 1997;46:321-326.

11. Webster J, Page MD, Bevan JS, Richards SH, Douglas-John AG, Scanlon MF. Low recurrence rate after partial hypophysectomy for prolactinoma; the predictive value of dynamic prolactin function tests. Clin Endocrinol 1992; 36:35-44.

12. Bevan JS, Burke CW, Esiri MM, Adams CBT. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987;82:29-32.

13. Ross RJM, Grossman A, Bouloux P, Rees LH, Doniach I, Besser GM. The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol 1985;23:227-235.

14. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909.

15. van der Heijden PFM., de Wit W., Brownell J., Schoemaker J., Rolland, R. CV205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 1991;40:111-118.

16. Verhelst JA, Froud AL, Touzel R, Wass JA, Besser GM, Grossman AB. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double blind study. Acta Endocrinol 1991;125:385-391.

17. Homburg R, West C, Brownell J, Jacobs HS. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205 ±502, with bromocriptine in women with hyperpro-lactinemia. Clin Endocrinol (Oxf) 1990;32:565-571.

18. Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J Endocrinol Investig 1994; 17:51-57.

19. Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000;53(1):53-60.

20. De Luis DA, Becerra A, Lahera M, Botella JI, Valero, Varela C. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 2000;23(7):428-434.

21. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-728.

22. Ferrari C, Mattei A, Melis GB, et al. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201-1206.

23. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copen) 1992;126:489-494.

24. Webster J, Piscitelli G, Polli A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol (Oxf) 1993;39:323-329.

25. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline vs. bromocriptine. Results of a national multicenter randomized doubleblind study. Presse Med. 1995;24:753-757.

26. Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-2343.

27. Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409-413.

28. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537-546.

29. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-883.

30. Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574-3579.

31. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.

32. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999;22(5):354-359.

33. Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary 2000;2(4):277-281.

34. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro and macroprolactinomas in men. J Clin Endocrinol Metab 2000; 85(9):3053-3057.

35. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85(6):2247-2252.

36. Jeffcoate WJ, Pound N, Sturrock NDC, Lambourne J. Long-term follow-up of patients with hyperprolactinemia. Clin Endocrinol 1997;45:299-303.

37. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.

38. Bevan JS, Adams CBT, Burke CW, et al. Factors in the outcome of trans-sphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541-556.

39. Popovic V, Simic M, Ilic LJ, et al. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy. Clin Endocrinol 1998;48:103-108.

40. George LD, Nicolau N, Scanlon MF, Davies JS. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin Endocrinol (Oxf) 2000;53(5):595-599.

41. Esiri MM, Bevan JS, Burke CW, Adams CBT. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and non-functioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 1986; 63:383-388.

42. Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000;93 (Suppl 3):14-18.

43. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(12 Suppl):1121-1126.

Was this article helpful?

0 0

Post a comment